Boros Eszter, Holland Jason P
Department of Chemistry, Stony Brook University, Stony Brook, NY, USA.
Department of Chemistry, University of Zurich, Zurich, Switzerland.
J Labelled Comp Radiopharm. 2018 Jul;61(9):652-671. doi: 10.1002/jlcr.3590. Epub 2018 Mar 12.
Radiometals are becoming increasingly accessible and are utilized frequently in the design of radiotracers for imaging and therapy. Nuclear properties ranging from the emission of γ-rays and β -particles (imaging) to Auger electron and β and α-particles (therapy) in combination with long half-lives are ideally matched with the relatively long biological half-life of monoclonal antibodies in vivo. Radiometal labeling of antibodies requires the incorporation of a metal chelate onto the monoclonal antibody. This chelate must coordinate the metal under mild conditions required for the handling of antibodies, as well as provide high kinetic, thermodynamic, and metabolic stability once the metal ion is coordinated to prevent release of the radionuclide before the target site is reached in vivo. Herein, we review the role of different radiometals that have found applications of the design of radiolabeled antibodies for imaging and radioimmunotherapy. Each radionuclide is described regarding its nuclear synthesis, coordinative preference, and radiolabeling properties with commonly used and novel chelates, as well as examples of their preclinical and clinical applications. An overview of recent trends in antibody-based radiopharmaceuticals is provided to spur continued development of the chemistry and application of radiometals for imaging and therapy.
放射性金属越来越容易获得,并经常用于设计用于成像和治疗的放射性示踪剂。从γ射线和β粒子发射(成像)到俄歇电子以及β和α粒子发射(治疗)的核性质,再加上较长的半衰期,与单克隆抗体在体内相对较长的生物半衰期完美匹配。抗体的放射性金属标记需要将金属螯合物结合到单克隆抗体上。这种螯合物必须在处理抗体所需的温和条件下与金属配位,并且一旦金属离子配位后,要提供高动力学、热力学和代谢稳定性,以防止放射性核素在体内到达靶位点之前释放。在此,我们综述了不同放射性金属在设计用于成像和放射免疫治疗的放射性标记抗体中的作用。描述了每种放射性核素的核合成、配位偏好、与常用和新型螯合物的放射性标记特性,以及它们的临床前和临床应用实例。提供了基于抗体的放射性药物的最新趋势概述,以推动放射性金属在成像和治疗方面的化学和应用的持续发展。